Table 2 Clinicopathological and genetic characteristics of Iranian CRC cases.
| Â | Iranian | Â | Â | Â | Â |
|---|---|---|---|---|---|
| Â | All | non-MSI-H | MSI-H | Odds Ratio | P |
Number of patients | 53 | 39 (74)a | 14 (26)a | Â | Â |
Mean Age | 59.8+12.7 - | 59.9+12.7 - | 59.4+13.1 - | Â | 0.90 |
Gender | 53 | Â | Â | Â | 0.52 |
   Female | 19(36) | 13(33) | 6(43) | 1 |  |
   Male | 34(64) | 26(67) | 8(57) | 0.67(0.19–2.33) |  |
Site | 53 | Â | Â | Â | 0.00 |
   Distal | 40(76) | 37(95) | 3(21) | 1 |  |
   Proximal | 13(24) | 2(5) | 11(79) | 66.67(10–500.00) |  |
Mucin Production | NA | Â | Â | Â | Â |
   None | NA |  |  |  |  |
   < 50% | NA |  |  |  |  |
   > 50% | NA |  |  |  |  |
Differentiation | 53 | Â | Â | Â | 0.00 |
   Well | 29(54) | 26(67) | 3(22) | 1 |  |
   Moderate | 22(42) | 13(33) | 9(64) | 6(1.38–26.00) |  |
   Poor | 2(4) | 0 | 2(14) | NA |  |
Stage | 53 | Â | Â | Â | 0.67 |
   Stage 1 | 0 | 0 | 0 | NA |  |
   Stage 2 | 12(23) | 10(26) | 2(14) | 1 |  |
   Stage 3 | 37(70) | 26(67) | 11(79) | 0.60(0.04–9.16) |  |
   Stage 4 | 4(7) | 3(7) | 1(7) | 1.27(0.12–13.58) |  |
BRAF | 53 | Â | Â | Â | 0.09 |
   Wild type | 52(98) | 39(100) | 13(93) |  |  |
   V600E | 1(2) | 0 | 1(7) | NA |  |
hMLH1 methylation (MSP) | 53 | Â | Â | Â | 0.00 |
   Unmethylation | 42(79) | 38(97) | 4(29) | 1 |  |
   Methylation | 11(21) | 1(3) | 10(71) | 95.00(9.53–946.94) |  |
p16 methylation (MSP) | 53 | Â | Â | Â | 0.00 |
   Unmethylation | 45(85) | 38(97) | 7(50) | 1 |  |
   Methylation | 8(15) | 1(3) | 7(50) | 38.00(4.03–358.74) |  |
hMLH1 expression by IHC | 25 | Â | Â | Â | 0.00 |
   Normal | 15(60) | 12(100) | 3(23) |  |  |
   Negative | 10(40) | 0 | 10(77) | NA |  |
hMSH2 expression by IHC | 25 | Â | Â | Â | 1.00 |
   Normal | 24(96) | 12(100) | 12(92) |  |  |
   Negative | 1(4) | 0 | 1(8) | NA |  |